379 related articles for article (PubMed ID: 30717444)
1. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.
Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444
[TBL] [Abstract][Full Text] [Related]
2. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
3. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
4. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
5. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer.
Ao X; Yang Y; Li W; Tan Y; Guo W; Ao L; He X; Wu X; Xia J; Xu X; Guo J
J Immunother; 2019 Oct; 42(8):284-296. PubMed ID: 31261167
[TBL] [Abstract][Full Text] [Related]
6. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Li Y; Hermanson DL; Moriarity BS; Kaufman DS
Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model.
Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X
J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
9. NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44.
Klapdor R; Wang S; Morgan MA; Zimmermann K; Hachenberg J; Büning H; Dörk T; Hillemanns P; Schambach A
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680456
[TBL] [Abstract][Full Text] [Related]
10. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
12. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies.
Luanpitpong S; Poohadsuan J; Klaihmon P; Issaragrisil S
J Immunol Res; 2021; 2021():5562630. PubMed ID: 34337077
[TBL] [Abstract][Full Text] [Related]
13. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
14. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
15. CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
Söhngen C; Thomas DJ; Skowron MA; Bremmer F; Eckstein M; Stefanski A; Driessen MD; Wakileh GA; Stühler K; Altevogt P; Theodorescu D; Klapdor R; Schambach A; Nettersheim D
FEBS J; 2023 Oct; 290(20):4864-4876. PubMed ID: 37254618
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
[TBL] [Abstract][Full Text] [Related]
18. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
19. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
Zhuang X; Long EO
Front Immunol; 2022; 13():840844. PubMed ID: 35585985
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
